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INTRODUCTION 
 
Background: ICU patients often receive glycemic control to 
mitigate the negative effects of prolonged hyperglycemia. 
However, results of glycemic control protocols have been 
mixed. Quality and consistency can be variable, leading to 
sub-optimal outcomes due to both patient-specific and 
external factors. In particular, intensive insulin therapy can 
lead to risk of iatrogenic hypoglycemia. 
  
Objective: To report initial clinical pilot results of the 
computerised STAR glycemic control protocol in a Hungarian 
and New Zealand ICU. 
Christchurch Gyula 
Patients 
Number of episodes 38 15 
Hours of control 3763 1168 
Workload 
# BG measurements: 1948 622 
Measures/day: 12.4 12.8 
Control performance 
BG median [IQR] (mmol/L): 6.1 [5.6 - 6.8] 6.0 [5.4 - 6.8] 
% BG within 4.4 – 7.0 mmol/L 77.8 72.7 
% BG within 4.4 – 8.0 mmol/L 89.4 80.4 
% BG within 8.0 – 10.0 mmol/L 6.1 10.0 
% BG > 10.0 mmol/L 3.0 2.2 
Safety 
% BG < 4.4 mmol/L 1.54 4.85 
% BG < 4.0 mmol/L 0.87 2.43 
% BG < 2.2 mmol/L 0.0 0.0 
# patients < 2.2 mmol/L 0 0 
Clinical interventions 
Median insulin rate [IQR] (U/hr): 3.0 [1.5 - 4.5] 2.5 [1.0 - 4.5] 
Median [IQR] enteral nutrition rate (g of carb/hr): 4.9 [0.0 - 6.1] 4.4 [2.4 - 5.5] 
Median [IQR] parenteral nutrition rate (g of carb/hr): 0.0 [0.0 - 0.0] 3.4 [1.6- 4.2] 
Table 1: Summary table of results from the clinical trial. Overall, the results show high control performance and low clinical effort, 
with safety preserved and no patients experiencing episodes of severe hyperglycemia. 
CONCLUSIONS 
 
STAR was equally effective in two ICUs, across geographically distinct clinical 
units, patients, and clinical practice. No significant difference was seen using 
infusion or bolus insulin. The STAR framework was readily transposed and 
quality glycemic control was achieved. 
METHODS 
 
15 pilot episodes (1168 hours) using STAR at Kálmán Pándy Hospital (Gyula, 
Hungary) are directly compared to 38 episodes (3763 hours) in Christchurch 
Hospital. Only patients with a target range of 4.4 - 8.0 mmol/L are included. 
Performance is assessed by percentage of (hourly re-sampled) BG 
measurements in glycemic bands. Safety is assessed by numbers of patients 
with severe hypoglycemia (BG < 2.2mmol/L) and degree of mild hypoglycemia 
(%BG<4.0mmol/L). Clinical effort is assessed as average BG measurements per 
day. 
 
Gyula administers insulin as constant infusions, and STAR actively controls both 
enteral and parenteral nutrition inputs. Christchurch uses insulin boluses, and 
STAR actively controls enteral nutrition (parenteral nutrition is clinically 
determined). Measurements were 1-3-hourly, with available intervals determined 
by STAR, and chosen by nursing staff. 
 
STAR determines optimal combinations of nutrition and insulin by identifying 
patient-specific insulin sensitivity (SI), and using stochastic forecasting to predict 
how patient condition is likely to change over the next 1-3 hours. 
RESULTS 
 
STAR was able to target BG to an equivalent level in two distinct 
ICUs, with cohort BG at 6.0 [5.4 - 6.8] mmol/L (Gyula) and 6.1 [5.6 
- 6.8] mmol/L (Christchurch). Effort was similar (12.3 and 12.8 
measurements/day in Gyula and Christchurch, respectively).  
 
Gyula performance/safety: 72.7% and 80.43% of BG in 4.4-7.0 and 
4.4-8.0mmol/L bands and 2.2% BG<4.0mmol/L. Christchurch 
performance/safety: 77.8% and 89.43% of BG in the 4.4-7.0 and 
4.4-8.0mmol/L bands and 0.87% BG<4.0mmol/L. There were no 
severe hypoglycemic events during STAR in either ICU.  
 
Performance differences were due to 1 Gyula patient without 
whom all metrics were within 0.1-1.0% difference. Insulin and 
nutrition inputs were comparable, with Gyula patients receiving 
increased nutrition inputs due to clinical practice. 
 
BG distributions in Christchurch were markedly similar to those 
predicted by virtual trials. 
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Figure 1: A schematic of the ICING model used to generate BG 
predictions with STAR. STAR is run on a tablet by the bedside 
(pictured). 
Figure 2: BG cumulative density functions from Christchurch Pilot trial and virtual trials using the N=371 SPRINT cohort (LHS). 
These two curves are remarkably similar, showing good agreement between the predicted and observed results in a single ICU. 
BG distributions from STAR Christchurch and Gyula are overlaid (RHS), showing the transferability of the STAR protocol. 
Removal of a single outlier patient makes a dramatic difference to Gyula results. 
